1 Barragan P, Podzamczer D. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin Pharmacother, 2008, 9: 2363-2375？？
[2]
2 Cvetkovic R S, Goa K L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs, 2003, 63: 769-802？？
[3]
3 Kaplan S S, Hicks C B. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother, 2005,6: 1573-1585？？
[4]
4 Manosuthi W, Kiertiburanakul S, Amornnimit W, et al. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. AIDS Res Ther, 2009, 6: 30？？
[5]
5 Josephson F, Andersson M C, Flamholc L, et al. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients. Eur J Clin Pharmacol, 2010, 66: 349-357
[6]
6 Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 2003, 47: 350-359？？
[7]
7 DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://AIDSinfo.nih.gov., 2009
[8]
8 Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr, 2003, 33: 594-600？？
[9]
9 Hammer S M, Eron J J Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama, 2008, 300: 555-570？？
[10]
10 Thompson M A, Aberg J A, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Jama, 2010, 304: 321-333？？
[11]
11 la Porte C J, Colbers E P, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother, 2004, 48: 1553-1560？？
[12]
12 Sham H L, Kempf D J, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother, 1998, 42: 3218-3224
[13]
13 D''Avolio A, Siccardi M, Sciandra M, et al. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci, 2007,859: 234-240
[14]
14 Colombo S, Guignard N, Marzolini C, et al. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 810: 25-34
[15]
15 Droste J A, Verweij-Van Wissen C P, Burger D M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit, 2003, 25: 393-399
[16]
16 Hirano A, Takahashi M, Kinoshita E, et al. High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma. Biol Pharm Bull,2010, 33: 1426-1429
[17]
17 Proust V, Toth K, Hulin A, et al. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J Chromatogr B Biomed Sci Appl, 2000, 742:453-458？？
[18]
18 Marzolini C, Beguin A, Telenti A, et al. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 774: 127-140？？
[19]
19 Ray J, Pang E, Carey D. Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 775: 225-230
[20]
20 Takahashi M, Yoshida M, Oki T, et al. Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. Biol Pharm Bull, 2005, 28: 1286-1290？？
[21]
21 Usami Y, Oki T, Nakai M, et al. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz. Chem Pharm Bull, 2003, 51: 715-718？？
[22]
22 Elens L, Veriter S, Di Fazio V, et al. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clin Chem, 2009, 55: 170-174
[23]
23 Remmel R P, Kawle S P, Weller D, et al. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma. Clin Chem, 2000, 46: 73-81
[24]
24 Solas C, Poizot-Martin I, Drogoul M P, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol, 2004, 57: 436-440？？
[25]
25 Gavard L, Gil S, Peytavin G, et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol, 2006, 195: 296-301？？
